Principal Financial Group Inc. Sells 7,823 Shares of Illumina, Inc. (NASDAQ:ILMN)

Principal Financial Group Inc. lessened its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 479,219 shares of the life sciences company's stock after selling 7,823 shares during the quarter. Principal Financial Group Inc. owned about 0.30% of Illumina worth $64,038,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Creative Planning lifted its stake in shares of Illumina by 3.3% in the 3rd quarter. Creative Planning now owns 16,679 shares of the life sciences company's stock valued at $2,175,000 after acquiring an additional 535 shares during the last quarter. Sequoia Financial Advisors LLC raised its position in Illumina by 6.6% in the third quarter. Sequoia Financial Advisors LLC now owns 4,944 shares of the life sciences company's stock valued at $645,000 after purchasing an additional 307 shares during the last quarter. Bank Pictet & Cie Europe AG acquired a new stake in shares of Illumina during the third quarter valued at about $383,000. Greenleaf Trust grew its holdings in shares of Illumina by 7.9% during the third quarter. Greenleaf Trust now owns 4,659 shares of the life sciences company's stock worth $608,000 after purchasing an additional 341 shares during the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Illumina by 196.6% in the third quarter. International Assets Investment Management LLC now owns 45,383 shares of the life sciences company's stock valued at $59,180,000 after buying an additional 30,080 shares during the period. Institutional investors own 89.42% of the company's stock.

Illumina Stock Down 3.1 %

NASDAQ ILMN traded down $3.00 on Friday, reaching $94.20. The company had a trading volume of 4,225,715 shares, compared to its average volume of 2,990,509. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company's fifty day moving average is $127.98 and its 200 day moving average is $134.01. Illumina, Inc. has a 52-week low of $93.50 and a 52-week high of $156.66. The stock has a market capitalization of $14.92 billion, a P/E ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays lowered shares of Illumina from an "equal weight" rating to an "underweight" rating and cut their price target for the stock from $130.00 to $100.00 in a report on Monday, February 10th. JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Piper Sandler upped their target price on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and lowered their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.